Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.44 -5.3%	$1.77	$0.99 ▼ $6.74	$77.13M	2.74	1.15 million shs	935,451 shs
ELUT Elutia	$2.04 +0.5%	$1.96	$1.61 ▼ $5.12	$83.46M	0.88	25,923 shs	15,286 shs
MBRX Moleculin Biotech	$0.67 +5.9%	$0.61	$0.25 ▼ $3.65	$18.97M	1.39	10.38 million shs	2.13 million shs
MGX Metagenomi	$2.25 -2.2%	$1.84	$1.23 ▼ $4.92	$85.98M	-0.14	925,210 shs	317,557 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-5.26%	-13.25%	-10.00%	+7.46%	-79.72%
ELUT Elutia	+0.49%	+6.25%	-5.56%	0.00%	-44.11%
MBRX Moleculin Biotech	+5.91%	+17.30%	+91.40%	-35.43%	-78.89%
MGX Metagenomi	-2.17%	-7.41%	+39.75%	+39.75%	-42.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.3146 of 5 stars	3.5	4.0	1.1	0.8	0.6
ELUT Elutia	3.4638 of 5 stars	3.5	5.0	1.9	3.3	0.6
MBRX Moleculin Biotech	2.7377 of 5 stars	3.5	2.0	2.4	1.7	1.3
MGX Metagenomi	2.4195 of 5 stars	3.5	4.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$14.43	901.98% Upside
ELUT Elutia	3.00	Buy	$8.00	292.16% Upside
MBRX Moleculin Biotech	3.00	Buy	$4.00	501.41% Upside
MGX Metagenomi	3.00	Buy	$13.00	477.78% Upside

Current Analyst Ratings Breakdown

Latest MBRX, MGX, ELUT, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/9/2025	ELUT Elutia	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
ELUT Elutia	$24.38M	3.44	N/A	N/A	($1.31) per share	-1.56
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
MGX Metagenomi	$52.29M	1.61	N/A	N/A	$6.28 per share	0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
ELUT Elutia	-$53.95M	-$1.93	N/A	N/A	N/A	-168.23%	N/A	-96.70%	8/6/2025 (Estimated)
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-278.80%	-100.11%	8/4/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)

Latest MBRX, MGX, ELUT, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	MGX Metagenomi	-$0.62	N/A	N/A	N/A	$7.72 million	N/A
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.42	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/8/2025	Q1 2025	ELUT Elutia	-$0.20	-$0.21	-$0.01	-$0.21	$6.65 million	$6.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	3.96	3.96
ELUT Elutia	N/A	0.81	0.70
MBRX Moleculin Biotech	N/A	1.35	1.35
MGX Metagenomi	N/A	5.85	5.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
ELUT Elutia	74.03%
MBRX Moleculin Biotech	15.52%
MGX Metagenomi	N/A

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
ELUT Elutia	27.60%
MBRX Moleculin Biotech	2.10%
MGX Metagenomi	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
ELUT Elutia	180	41.12 million	29.77 million	Not Optionable
MBRX Moleculin Biotech	20	30.21 million	29.57 million	Not Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A

MBRX, MGX, ELUT, and CABA Headlines

Recent News About These Companies

Metagenomi (MGX) Presents Latest in Gene Editing Technologies

July 29, 2025 | msn.com

Metagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT Meeting

July 14, 2025 | msn.com

Metagenomi (NASDAQ:MGX) Stock Price Up 22% - Still a Buy?

July 10, 2025 | marketbeat.com

Insider Selling: Metagenomi, Inc. (NASDAQ:MGX) CEO Sells 10,785 Shares of Stock

June 10, 2025 | insidertrades.com

Metagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 16, 2025 | finance.yahoo.com

2MGX : Demystifying Metagenomi: Insights From 4 Analyst Reviews

May 15, 2025 | benzinga.com

Metagenomi Reports Promising Hemophilia A Study Results

May 14, 2025 | tipranks.com

Metagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 14, 2025 | finanznachrichten.de

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025 | globenewswire.com

Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025 | globenewswire.com

Metagenomi Leads The Charge With These 3 Penny Stocks

April 10, 2025 | uk.finance.yahoo.com

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Metagenomi, Inc. Common Stock (MGX) Latest After Hours Trades

March 31, 2025 | nasdaq.com

Biotech stocks slide as Marks resignation seen being negative for sector

March 31, 2025 | markets.businessinsider.com

Bullish: Analysts Just Made A Significant Upgrade To Their Metagenomi, Inc. (NASDAQ:MGX) Forecasts

March 27, 2025 | uk.finance.yahoo.com

Metagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2024 Financial Results

March 19, 2025 | finanznachrichten.de

Metagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna Collaboration

March 19, 2025 | tipranks.com

Metagenomi, Inc. Reports 2024 Financial Results and Pipeline Progress

March 18, 2025 | tipranks.com

Metagenomi files $250M mixed securities shelf

March 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, MGX, ELUT, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.44 -0.08 (-5.26%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.48 +0.05 (+3.13%)

As of 08/1/2025 07:59 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Elutia NASDAQ:ELUT

$2.04 +0.01 (+0.49%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.04 0.00 (0.00%)

As of 08/1/2025 04:10 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Moleculin Biotech NASDAQ:MBRX

$0.67 +0.04 (+5.91%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.62%)

As of 08/1/2025 07:49 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Metagenomi NASDAQ:MGX

$2.25 -0.05 (-2.17%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.22 -0.02 (-1.11%)

As of 08/1/2025 07:51 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time